Indivior PLC INDV Shareholders Urged to Contact The Gross Law Firm for Potential Class Action Lawsuit Before October 2024 Deadline

Investors of Indivior PLC INDV, the North Chesterfield, Virginia-based pharmaceutical company specializing in buprenorphine-based drugs for opioid dependence, are being called to action. A class action lawsuit for securities fraud regarding INDV is currently pending, and The Gross Law Firm is issuing a notice for shareholders.

Notice to Indivior PLC Investors

Following allegations of securities fraud, The Gross Law Firm is seeking to inform shareholders of Indivior PLC who have acquired shares during a predefined class period, that they may be eligible to be appointed as lead plaintiff in the case. The lawsuit aims to address potential discrepancies and misrepresentations that might have affected the value of the securities held by investors. Claimants invested in INDV stocks should consider contacting the firm prior to the October 1, 2024 deadline for a discussion on their legal rights.

Potential Lead Plaintiff Appointment

Investors with an interest in participating in the lawsuit are advised to get in touch with The Gross Law Firm. Representation can significantly impact the outcome for a shareholder in a class action suit. Appointed lead plaintiffs can make decisions on behalf of all members of the lawsuit and are often instrumental in directing the litigation process.

As legal proceedings progress, shareholders of Indivior PLC's INDV securities are therefore encouraged to exercise their rights and consider their standing within the larger context of the securities fraud class action lawsuit.

Indivior, Lawsuit, Investment